Journal Article

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma

Coffman‐D'Annibale, Kelley L., Wang, Xin Wei, Kleiner, David E., Greten, Tim F., Budhu, Anuradha, Myojin, Yuta, Cam, Maggie, Wang, Sophie, Finney, Richard, Figg, William D., Wood, Bradford J., Brar, Gagandeep, Redd, Bernadette, Xie, Changqing, Monge, Cecilia, Levy, Elliot B., Hrones, Donna, Steinberg, Seth M.

2024

Overview

Background Current standard of care for advanced biliary tract cancer (BTC) is gemcitabine, cisplatin plus anti‐PD1/PD‐L1, but response rates are modest. The purpose of this study was to explore the efficacy and safety of durvalumab (anti‐PD‐L1) and tremelimumab (anti‐CTLA‐4), with and without an interventional radiology (IR) procedure in advanced BTC. Methods Eligible patients with advanced BTC who had received or refused at least one prior line of systemic therapy were treated with tremelimumab and durvalumab for four combined doses followed by monthly durvalumab alone with and without an IR procedure until the progression of disease or unacceptable toxicity. Objective response was assessed through CT or MRI by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) every 8 weeks. Adverse events (AEs) were recorded and managed. The primary endpoint was 6‐month progression‐free survival (PFS). Results Twenty‐three patients with advanced BTC were enrolled; 17 patients were assigned to treatment with durvalumab and tremelimumab (Durva/Treme); and 6 patients were treated with the combination of durvalumab, tremelimumab plus IR procedure (Durva/Treme + IR). The best clinical responses in the Durva/Treme arm were partial response (n = 1), stable disease (n = 5), progressive disease (n = 5), and in the Durva/Treme + IR arm: partial response (n = 0), stable disease (n = 3), progressive disease (n = 3). The median PFS was 2.2 months (95% CI: 1.3–3.1 months) in the Durva/Treme arm and 2.9 months (95% CI: 1.9–4.7 months) in the Durva/Treme + IR arm (p = 0.27). The median OS was 5.1 months (95% CI: 2.5–6.9 months) in the Durva/Treme arm and 5.8 months (95% CI: 2.9–40.1 months) in the Durva/Treme + IR arm (p = 0.31). The majority of AEs were grades 1–2. Conclusion Durva/Treme and Durva/Treme + IR showed similar efficacy. With a manageable safety profile. Larger studies are needed to fully characterize the efficacy of Durva/Treme ± IR in advanced BTC. The purpose of this study was to explore the efficacy and safety of two ICIs, durvalumab and tremelimumab, with and without an interventional radiology (IR) procedure in patients with advanced BTC. Durva/Treme + IR showed no difference in efficacy compared with Durva/Treme alone, but the safety profile of both cohorts was manageable. Larger studies are needed to fully characterize efficacy of Durva/Treme with or without IR in advanced BTCs.

• Publisher: John Wiley & Sons, Inc,Wiley
• Subject: Ablation / Antibodies, Monoclonal / Antibodies, Monoclonal, Humanized / Bile Duct Neoplasms / Biliary Tract / biliary tract cancer / Biliary tract diseases / Biopsy / Cancer therapies / Carcinoma / Chemotherapy / Cholangiocarcinoma / Cisplatin / cryoablation / CTLA-4 protein / durvalumab / Gastrointestinal Neoplasms / Gemcitabine / Gene expression / Genomics / Humans / immune checkpoint inhibitor / Immune Checkpoint Inhibitors / Immunotherapy / interventional radiology / Medical prognosis / Monoclonal antibodies / Mutation / Patients / PD-1 protein / PD-L1 protein / Precision medicine / Radiofrequency Ablation / Response rates / Solid tumors / Targeted cancer therapy / Toxicity / tremelimumab / Tumors